

## 270-ISMS28 Establishment of a Unique Bio-conversion Platform for Drug Discovery

○Shinya OKUBO<sup>1</sup>, Tomoyuki SHIBUGUCHI<sup>2</sup>, Eri ENA<sup>3</sup>, Akifumi OKUDA<sup>1</sup>

<sup>1</sup>Technology Cross Point Laboratory, hhc Data Creation Center, Eisai Co., Ltd., <sup>2</sup>Neurology Tsukuba Research Department, Discovery, Medicine Creation, Neurology Business Group, Eisai Co., Ltd., <sup>3</sup>Analytical Research. Pharmaceutical Science & Technology Core Function Unit, Medicine Development Center, Eisai Co., Ltd.

---

Bio-conversion utilizing microorganisms is a practical tool for drug discovery. One of the feature is various functionalization of the non-activated sites selectively under mild conditions. We established a unique bio-conversion platform by combining a miniaturized fermentation system and existing infrastructures of Eisai natural product lead discovery. Our platform contributes to a wide range of programs from early to late drug discovery stage. Capability of our platform has been expanded through technology integration of microbial and chemical conversion. Our strength is to be able to flexibly change the synthetic strategy and respond quickly to the needs by timely and interactive technical communication with medicinal chemists. In this poster, we will discuss the potential applications and future plans of our platform.